Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-stage tumor types from three phase I/II trials of durvalumab (± the anti-CTLA4 therapy tremelimumab). Higher pretreatment variant allele frequencies (VAF) were associated with poorer overall survival (OS) and other known prognostic factors, but not objective response, suggesting a prognostic role for patient outcomes. On-treatment reductions in VAF and lower on-treatment VAF were independently associated with longer progression-free survival and OS and increased objective response rate, but not prognostic variables, suggesting that on-treatment ctDNA dynamics are predictive of benefit from immune checkpoint blockade. Accordingly, we propose a concept of “molecular response” using ctDNA, incorporating both pretreatment and on-treatment VAF, that predicted long-term survival similarly to initial radiologic response while also permitting early differentiation of responders among patients with initially radiologically stable disease. Significance: In a pan-cancer analysis of immune checkpoint blockade, pretreatment ctDNA levels appeared prognostic and on-treatment dynamics predictive. A “molecular response” metric identified long-term responders and adjudicated benefit among patients with initially radiologically stable disease. Changes in ctDNA may be more dynamic than radiographic changes and could complement existing trial endpoints. This article is highlighted in the In This Issue feature, p. 1775
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, integration of longitudinal blood-based assays such as circulating-tumor DNA (ctDNA; ref. 216), which are easier to implement and less invasive as opposed to longitudinal tumor biopsies, is under investigation as a method to monitor responses to ICT.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Self-citationAtezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Cited by
Liquid biopsy: current technology and clinical applications
Nikanjam, M., Kato, S., & Kurzrock, R. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01351-y · Cited by 931
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.017 · Cited by 683
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646
Detection and characterization of lung cancer using cell-free DNA fragmentomes
Mathios, D., Johansen, J. S., Cristiano, S., Medina, J. E., Phallen, J., Larsen, K. R., Bruhm, D. C., Niknafs, N., Ferreira, L., Adleff, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24994-w · Cited by 472
Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.018 · Cited by 315
Oh, D.-Y., Lee, K.-H., Lee, D.-W., Yoon, J., Kim, T.-Y., Bang, J.-H., Nam, A.-R., Oh, K.-S., Kim, J.-M., Lee, Y., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00043-7 · Cited by 311
Self-citationUsing Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02615 · Cited by 292
Yarchoan, M., Gane, E. J., Marron, T. U., Perales-Linares, R., Yan, J., Cooch, N., Shu, D. H., Fertig, E. J., Kagohara, L. T., Bartha, G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02894-y · Cited by 250
Xia, L., Mei, J., Kang, R., Deng, S., Chen, Y., Yang, Y., Feng, G., Deng, Y., Gan, F., Lin, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3044 · Cited by 244
Palmer, C. D., Rappaport, A. R., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S.-J., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01937-6 · Cited by 236
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 231
Mino-Kenudson, M., Schalper, K., Cooper, W., Dacic, S., Hirsch, F. R., Jain, D., Lopez-Rios, F., Tsao, M. S., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 226
Turner, N. C., Swift, C., Jenkins, B., Kilburn, L., Coakley, M., Beaney, M., Fox, L., Goddard, K., Garcia-Murillas, I., Proszek, P., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.005 · Cited by 208
Sanz-Garcia, E., Zhao, E., Bratman, S. V., & Siu, L. L. (2022) · Science Advances · doi:10.1126/sciadv.abi8618 · Cited by 193
Current and Future Clinical Applications of ctDNA in Immuno-Oncology
Stadler, J.-C., Belloum, Y., Deitert, B., Sementsov, M., Heidrich, I., Gebhardt, C., Keller, L., & Pantel, K. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1718 · Cited by 170
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Anagnostou, V., Ho, C., Nicholas, G., Juergens, R. A., Sacher, A., Fung, A. S., Wheatley-Price, P., Laurie, S. A., Levy, B., Brahmer, J. R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02598-9 · Cited by 170
Peng, Y., Mei, W., Ma, K., & Zeng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763790 · Cited by 167
Widman, A. J., Shah, M. J., Frydendahl, A., Halmos, D., Khamnei, C. C., Øgaard, N., Rajagopalan, S., Arora, A., Deshpande, A. S., Hooper, W. F., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03040-4 · Cited by 169
Banna, G. L., Hassan, M. A., Signori, A., Giunta, E. F., Maniam, A., Anpalakhan, S., Acharige, S. M., Ghose, A., & Addeo, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6837 · Cited by 163
Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02015-7 · Cited by 160
Self-citationRecent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
Wang, B., Pei, J., Xu, S., Liu, J., & Yu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1246682 · Cited by 158
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
Gouda, M. A., Jankú, F., Wahida, A., Buschhorn, L., Schneeweiß, A., Karim, N. A., de Miguel‐Pérez, D., Re, M. D., Russo, A., Curigliano, G., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.007 · Cited by 143
de Miguel‐Pérez, D., Russo, A., Arrieta, O. G., Ak, M., Barrón, F., Gunasekaran, M., Mamindla, P., Lara‐Mejía, L., Peterson, C. B., Er, M. E., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02379-1 · Cited by 127
Powles, T. B., Carroll, D. K., Chowdhury, S., Gravis, G., Joly, F., Carles, J., Fléchon, A., Maroto, P., Petrylak, D. P., Rolland, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01317-6 · Cited by 123
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Thompson, J. C., Carpenter, E. L., Silva, B. A., Rosenstein, J., Chien, A. L., Quinn, K., Espenschied, C. R., Mak, A. J., Kiedrowski, L. A., Lefterova, M. I., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00321 · Cited by 119
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
Adashek, J. J., Jankú, F., & Kurzrock, R. (2021) · Cancers · doi:10.3390/cancers13143600 · Cited by 110
Variant allele frequency: a decision-making tool in precision oncology?
Bielo, L. B., Trapani, D., Repetto, M., Crimini, E., Valenza, C., Belli, C., Criscitiello, C., Marra, A., Subbiah, V., & Curigliano, G. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.011 · Cited by 109
Schoenfeld, A. J., Antonia, S. J., Awad, M. M., Felip, E., Gainor, J. F., Gettinger, S. N., Hodi, F. S., Johnson, M. L., Leighl, N. B., Lovly, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2151 · Cited by 107
Self-citationDong, S., Wang, Z., Zhang, J., Yan, B., Zhang, C., Gao, X., Sun, H., Li, Y.-S., Yan, H., Tu, H.-Y., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1779 · Cited by 106
Duffy, M. J. (2023) · Tumor Biology · doi:10.3233/tub-220044 · Cited by 103
Liquid Biopsy Based on Cell-Free DNA and RNA
Loy, C., Ahmann, L. S., Vlaminck, I. D., & Gu, W. (2024) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110222-111259 · Cited by 94
Vega, D. M., Nishimura, K. K., Zariffa, N. M.-D., Thompson, J. C., Hoering, A., Cilento, V. J., Rosenthal, A., Anagnostou, V., Baden, J. F., Beaver, J. A., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00372 · Cited by 93
Caputo, V., Ciardiello, F., Corte, C. M. D., Martini, G., Troiani, T., & Napolitano, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00125 · Cited by 89
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
Thompson, J. C., Scholes, D. G., Carpenter, E. L., & Aggarwal, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02445-1 · Cited by 85
Liquid biopsy into the clinics: Current evidence and future perspectives
Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 82
Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma
Hanna, G. J., Dennis, M. J., Scarfo, N., Mullin, M. S., Sethi, R. K. V., Sehgal, K., Annino, D. J., Goguen, L. A., Haddad, R. I., Tishler, R. B., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0590 · Cited by 77
Rose, K. M., Huelster, H. L., Meeks, J. J., Faltas, B. M., Sonpavde, G., Lerner, S. P., Ross, J. S., Spiess, P. E., Grass, G. D., Jain, R., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00725-2 · Cited by 74
Paz-Ares, L. G., Garassino, M. C., Chen, Y., Reinmuth, N., Hotta, K., Poltoratskiy, A., Trukhin, D. V., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1689 · Cited by 73
Mack, P. C., Miao, J., Redman, M. W., Moon, J., Goldberg, S. B., Herbst, R. S., Melnick, M. A., Walther, Z., Hirsch, F. R., Politi, K. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0741 · Cited by 71
Liquid biopsies across the cancer care continuum
Landon, B. V., Annapragada, A. V., Niknafs, N., Velculescu, V. E., & Anagnostou, V. (2025) · Nature Medicine · doi:10.1038/s41591-025-04093-9 · Cited by 71
Weber, S., van der Leest, P., Donker, H. C., Schlange, T., Timens, W., Tamminga, M., Hasenleithner, S. O., Graf, R., Moser, T., Spiegl, B., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00182 · Cited by 68
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 69
Al-Showbaki, L., Wilson, B. E., Tamimi, F., Moltó, C., Mittal, A., Cescon, D. W., & Amir, E. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005854 · Cited by 65
Duffy, M. J., & Crown, J. P. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac121 · Cited by 65
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers
Gouda, M. A., Huang, H. J., Piha-Paul, S. A., Call, S. G., Karp, D. D., Fu, S., Naing, A., Subbiah, V., Pant, S., Dustin, D. J., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00512 · Cited by 65
Empowering effective biomarker-driven precision oncology: A call to action
Lawler, M., Keeling, P., Kholmanskikh, O., Minnaard, W., Moehlig-Zuttermeister, H., Normanno, N., Philip, R., Popp, C., Salgado, R., Santiago-Walker, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114225 · Cited by 63
The molecular tumor burden index as a response evaluation criterion in breast cancer
Yi, Z., Ma, F., Rong, G., Liu, B., Guan, Y., Li, J., Sun, X., Wang, W., Guan, X., Mo, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00662-9 · Cited by 60
The Role of Cell-Free DNA in Cancer Treatment Decision Making
Telekes, A., & Horváth, A. (2022) · Cancers · doi:10.3390/cancers14246115 · Cited by 58
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
Shields, M. D., Chen, K., Dutcher, G., Patel, I., & Pellini, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169006 · Cited by 58
Jiang, T., Chen, J., Xu, X., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., Yao, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01479-4 · Cited by 57
Deciphering radiological stable disease to immune checkpoint inhibitors
Luo, J., Wu, S., Rizvi, H. A., Zhang, Q., Egger, J. V., Osorio, J. C., Schoenfeld, A. J., Plodkowski, A. J., Ginsberg, M. S., Callahan, M. K., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.450 · Cited by 57
Self-citationvan der Leest, P., Hiddinga, B. I., Miedema, A., Azpurua, M. L. A., Rifaela, N., ter Elst, A., Timens, W., Groen, H. J. M., van Kempen, L. C. L. T., Hiltermann, T. J. N., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13090 · Cited by 55
Pellini, B., Madison, R. W., Childress, M. A., Miller, S. T., Gjoerup, O. V., Cheng, J. H., Huang, R. S. P., Krainock, M. R., Gupta, P., Zou, W., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1578 · Cited by 55
Zou, W., Yaung, S. J., Fuhlbrück, F., Ballinger, M. D., Peters, E. J., Palma, J. F., Shames, D. S., Gandara, D. R., Jiang, Y., & Patil, N. S. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00057 · Cited by 54
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 54
Progresses in biomarkers for cancer immunotherapy
Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 53
Fujii, Y., Ono, A., Hayes, C. N., Aikata, H., Yamauchi, M., Uchikawa, S., Kodama, K., Teraoka, Y., Fujino, H., Nakahara, T., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02016-3 · Cited by 52
Soo, R. A., Martini, J.-F., van der Wekken, A. J., Teraoka, S., Ferrara, R., Shaw, A. T., Shepard, D., Calella, A. M., Polli, A., Toffalorio, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.021 · Cited by 52
Liquid Biopsies in Lung Cancer
Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023) · Cancers · doi:10.3390/cancers15051430 · Cited by 51
Liquid biopsies for residual disease and recurrence
Wan, J. C. M., Mughal, T. I., Razavi, P., Dawson, S., Moss, E. L., Govindan, R., Tan, I. B., Yap, Y. S., Robinson, W. A., Morris, C. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.001 · Cited by 50
Li, C., Shao, J., Li, P., Feng, J., Li, J., & Wang, C. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216365 · Cited by 50
Nuccio, A., Viscardi, G., Salomone, F., Servetto, A., Venanzi, F. M., Riva, S. T., Oresti, S., Ogliari, F. R., Viganò, M., Bulotta, A., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113404 · Cited by 49
Liu, Y., Altreuter, J., Bodapati, S., Cristea, S., Wong, C. J., Wu, C. J., & Michor, F. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100444 · Cited by 48
Dumbrava, E. E. I., Call, S. G., Huang, H. J., Stuckett, A. L., Madwani, K., Adat, A., Hong, D. S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100230 · Cited by 48
Wang, H., Zhou, F., Qiao, M., Li, X., Zhao, C., Cheng, L., Chen, X., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671874 · Cited by 48
Li, Z., Song, Z., Hong, W., Yang, N., Wang, Y., Jian, H., Liang, Z., Hu, S., Peng, M., Yu, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01897-y · Cited by 48
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 47
Rodrigues, M. J., Ramtohul, T., Rampanou, A., Sandoval, J. L., Houy, A., Servois, V., Mailly-Giacchetti, L., Pierron, G., Vincent‐Salomon, A., Cassoux, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53145-0 · Cited by 46
Xu, D., Wang, H., Bao, Q., Jin, K., Liu, M., Liu, W., Yan, X., Wang, L., Zhang, Y., Wang, G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56537-y · Cited by 44
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Jee, J., Brannon, A. R., Singh, R. K., Derkach, A., Fong, C. J., Lee, A. V., Gray, L., Pichotta, K., Luthra, A., Diosdado, M. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03195-0 · Cited by 44
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
Duchemann, B., Remón, J., Naigeon, M., Mezquita, L., Ferrara, R., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., et al. (2020) · Cancers · doi:10.3390/cancers12123625 · Cited by 43
Angeles, A. K., Christopoulos, P., Yuan, Z. K., Bauer, S., Janke, F., Ogrodnik, S. J., Reck, M., Schlesner, M., Meister, M. A., Schneider, M. A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00239-3 · Cited by 43
Dong, Q., Chen, C., Hu, Y., Zhang, W., Yang, X., Qi, Y., Zhu, C., Chen, X., Shen, X., & Ji, W. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2274123 · Cited by 43
Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of Care
Grothey, A. F. (2020) · New England Journal of Medicine · doi:10.1056/nejme2031294 · Cited by 42
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression
Topp, B. G., Channavazzala, M., Mayawala, K., de Alwis, D. P., Rubin, E. H., Snyder, A., Wolchok, J. D., & Ribas, A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.004 · Cited by 42
Martínez‐Sáez, O., Pascual, T., Brasó‐Maristany, F., Chic, N., González‐Farré, B., Sanfeliu, E., Rodríguez, A., Martínez, D., Galván, P., Rodríguez, A. B., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00218-8 · Cited by 41
Restrepo, J. C., Guevara, D. M., López, A. P., Palacios, J. F. M., & Liscano, Y. (2024) · Cancers · doi:10.3390/cancers16132338 · Cited by 41
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
Bertoli, E., Carlo, E. D., Basile, D., Zara, D., Stanzione, B., Schiappacassi, M., Conte, A. D., Spina, M., & Bearz, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310803 · Cited by 40
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology
Mazzeo, R., Sears, J., Palmero, L., Bolzonello, S., Davis, A. A., Gerratana, L., & Puglisi, F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103700 · Cited by 39
Pascual, J., Gil‐Gil, M., Proszek, P., Zielinski, C. C., Reay, A., Ruíz-Borrego, M., Cutts, R. J., Ciruelos, E., Feber, A., Muñoz-Mateu, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0956 · Cited by 38
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
Umemoto, K., Sunakawa, Y., Ueno, M., Furukawa, M., Mizuno, N., Sudo, K., Kawamoto, Y., Kajiwara, T., Ohtsubo, K., Okano, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02189-y · Cited by 37
Sorbini, M., Carradori, T., Togliatto, G., Vaisitti, T., & Deaglio, S. (2024) · Biomolecules · doi:10.3390/biom14040498 · Cited by 36
Backman, M., Fleur, L. L., Kurppa, P., Djureinovic, D., Elfving, H., Brunnström, H., Mattsson, J. S. M., Lindberg, A., Pontén, V., Eltahir, M., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5772 · Cited by 35
Liu, T., Yao, Q., & Jin, H. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.616209 · Cited by 34
da Silva, L. F. L., Saldanha, E. F., de Menezes, J. S. A., Pereira, L. H., dos Santos, J. A. R. D. B., Buonopane, I. R., de Souza, E. M., de Menezes, C. U. G., & Junior, G. L. L. (2025) · The Oncologist · doi:10.1093/oncolo/oyae344 · Cited by 32
Sun, B., Xun, Z., Zhang, N., Liu, K., Chen, X., & Zhao, H. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03158-4 · Cited by 32
Andrews, H. S., Zariffa, N. M.-D., Nishimura, K. K., Choi, S. H., Deng, S., Eisele, M., Espenschied, C. R., Goren, E., Guha, M., Hong, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3612 · Cited by 31
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
Parisi, C., Tagliamento, M., Belcaid, L., Aldea, M. D., Bayle, A., Remon-Masip, J., Italiano, A., Planchard, D., Besse, B., & Barlési, F. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100007 · Cited by 31
Li, Y., Xu, Z., Wang, S., Zhu, Y., Ma, D., Mu, Y., Ying, J., Li, J., & Xing, P. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14545 · Cited by 30
Schwartzberg, L. S., Li, G., Tolba, K. A., Bourla, A. B., Schulze, K., Gadgil, R. Y., Fine, A. D., Lofgren, K. T., Graf, R. P., Oxnard, G. R., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100386 · Cited by 30
Immunotherapy in lung cancer brain metastases
Paisana, E., Cascão, R., Alvoeiro, M., Félix, F., Martins, G., Guerreiro, C., Roque, R., Cruz, R., Pacheco, T. R., Amado, A. C., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00901-0 · Cited by 30
Galoș, D., Gorzo, A., Bălăcescu, O., & Sur, D. G. (2022) · Cells · doi:10.3390/cells11213493 · Cited by 30
Ai, X., Jia, B., He, Z., Zhang, J., Zhuo, M., Zhao, J., Wang, Z., Zhang, J., Fan, Z., Zhang, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02060-3 · Cited by 30
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development
Pal, A., Shinde, R., Miralles, M. S., Workman, P., & Bono, J. S. D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00489-x · Cited by 30
Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC
Cheng, M. L., Lau, C. J., Milan, M. S. D., Supplee, J. G., Riess, J. W., Bradbury, P. A., Jänne, P. A., Oxnard, G. R., & Paweletz, C. P. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00419 · Cited by 29
Zengin, Z. B., Weipert, C. M., Salgia, N., Dizman, N., Hsu, J., Meza, L., Chehrazi‐Raffle, A., Muddasani, R., Salgia, S. K., Malhotra, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0572 · Cited by 29
Xu, X., Ai, L., Hu, K., Liang, L., Lv, M., Wang, Y., Cui, Y., Li, W., Li, Q., Yu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51536-x · Cited by 29
Metadata
- Authors
- Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., Segal, N. H., Chaft, J. E., Hembrough, T., Barrett, J. C., & Hellmann, M. D.
- Affiliations
- 1Translational Medicine, Early Oncology, AstraZeneca, Gaithersburg, Maryland.
- Memorial Sloan Kettering Cancer Center (US)
- 3Early Oncology Statistics, AstraZeneca, Gaithersburg, Maryland.
- AstraZeneca (United States) (US)
- 5Division of Molecular Carcinogenesis and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
- Corresponding author
- Hellmann, Matthew D.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-12-01
- Volume
- 10
- Issue
- 12
- Pages
- 1842-1853
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8358981
- OpenAlex
- W3049083268
- Cited by
- 348
- References
- 53
- Citations by year
- 2026: 31 · 2025: 72 · 2024: 60 · 2023: 70 · 2022: 54 · 2021: 54 · 2020: 6
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- AstraZeneca (NCT01693562, NCT02087423, NCT02261220)
- Memorial Sloan Kettering Cancer Center (P30 CA008748)
- Damon Runyon Cancer Research Foundation (CI-98-18)
- Parker Institute for Cancer Immunotherapy
- NIH (T32-CA009207, K30-UL1TR00457)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- circulating tumor DNA, immune checkpoint blockade, durvalumab, tremelimumab, variant allele frequency, molecular response, prognostic factors, predictive biomarkers, overall survival, progression-free survival, objective response rate, pan-cancer analysis, CTLA-4 blockade
- MeSH terms
- Circulating Tumor DNA, Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.